Phase 2 Trial to Assess Osilodrostat as Treatment for Children with Cushing’s Disease
Novartis is launching a Phase 2 trial to assess the safety and efficacy of its investigational therapy osilodrostat — an inhibitor of cortisol synthesis — in children with Cushing’s disease. The Phase 2 trial (NCT03708900) is expected to enroll 12 pediatric patients, from 6 to 18 years, who…